Insulet Corporation highlights diabetes management leadership and market growth in new investor presentation
I'm PortAI, I can summarize articles.
Insulet Corporation showcased its leadership in diabetes management at the J.P. Morgan 44th Annual Healthcare Conference. The company highlighted its FDA-cleared Automated Insulin Delivery (AID) system, which is the most prescribed in the U.S. Insulet anticipates approximately $2.7 billion in revenue for 2025 and has over 600,000 active customers globally. The company has contributed to two-thirds of the AID market growth from 2020 to 2025, achieving a 26% CAGR and nearing a 50% share of global revenue in this segment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments